Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-02, Stock:LLY, The news for the past five days is as follows:
2018-07-26: NEWS1: Allergan Reports Strong Revenue Growth and Q2 2018 Earnings.NEWS2: Celgene Raises Revenue Guidance after Solid Growth in Q2 2018.NEWS3: Analysts’ Recommendations for Sanofi Stock before Q2 Results.NEWS4: AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up.NEWS5: AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up.NEWS6: Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan.NEWS7: Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan.NEWS8: Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up.NEWS9: Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up.NEWS10: Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan.NEWS11: LLY Crosses Above Average Analyst Target.NEWS12: LLY Crosses Above Average Analyst Target.NEWS13: Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, &apos;18 View Up.NEWS14: ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions.NEWS15: ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions.NEWS16: ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions.NEWS17: Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities.NEWS18: FOCUS-Amgen's new migraine drug hits insurance hurdles.NEWS19: FOCUS-Amgen's new migraine drug hits insurance hurdles.
2018-07-27: NEWS1: Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength.NEWS2: Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength.NEWS3: Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod.NEWS4: Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod.NEWS5: Merck Witnessed 5% Growth in Q2 2018.NEWS6: Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV&apos;s Elagolix Gets FDA Nod.NEWS7: Pfizer’s Q2 2018 Earnings: Analysts’ Estimates.NEWS8: Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength.NEWS9: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS10: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS11: New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production.
2018-07-30: NEWS1: What to Expect from Incyte’s Q2 2018 Earnings on July 31.NEWS2: How Celgene’s Otezla and Abraxane Did in Q2 2018.NEWS3: A Look at Celgene’s Financials in Q2 2018.NEWS4: WisdomTree U.S. Dividend ex-Financials Fund -- Insider Buying Index Registering 10.2%.NEWS5: WisdomTree U.S. Dividend ex-Financials Fund -- Insider Buying Index Registering 10.2%.NEWS6: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS7: Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute.
2018-07-31: NEWS1: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS2: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS3: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS4: Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss.NEWS5: Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss.NEWS6: November 16th Options Now Available For Eli Lilly.NEWS7: November 16th Options Now Available For Eli Lilly.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: What Analysts Recommend for Celgene Stock.
2018-08-01: NEWS1: Here's What's Going On at Eli Lilly and GlaxoSmithKline.NEWS2: Here's What's Going On at Eli Lilly and GlaxoSmithKline.NEWS3: Here&apos;s What&apos;s Going On at Eli Lilly and GlaxoSmithKline.NEWS4: Eli Lilly’s Q2 2018 Earnings: Human Pharmaceuticals Business.NEWS5: A Look at Merck’s Financial Position.NEWS6: Why The 'Heat Wave' For U.S. Pharma Could Continue This Month.NEWS7: Eli Lilly’s Q2 2018 Earnings: How Did Its Segments Perform?.NEWS8: Most Analysts Recommended a ‘Buy’ for Merck at End of July.NEWS9: Healthcare Bulls Are Feeling Great After Earnings.NEWS10: Eli Lilly: 9% Revenue Growth in Q2 2018 Exceeded Estimates.NEWS11: Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability.NEWS12: [$$] Trump is losing the war on drug prices.NEWS13: [$$] Trump’s fight with drugmakers will not solve healthcare crisis.

Answer: Rise